Latest News
- Min. Nadda Unveils ?13,000-Crore Bio-Pharma SHAKTI and Chemical Parks Push to Expand India’s Global Chemicals and Biologics Footprint
- Aurobindo Pharma Subsidiary Launches Generic Cancer Drug in US, Expands Oncology Portfolio in Global Generics Market
- KIMS Hospitals Introduces Adaptive Deep Brain Stimulation in India for Advanced Parkinson’s Treatment
AstraZeneca Announces $2 Billion Investment to Boost US Manufacturing Capabilities
The investment is part of AstraZeneca’s long-term vision of deploying around $50 billion in US-based manufacturing and research activities by 2030. As part of this phase, the company will upgrade its biologics manufacturing facility in Frederick and establish a new cutting-edge clinical manufacturing campus in Gaithersburg.
- By Newsdesk
- New Delhi
- Nov 24, 2025
AstraZeneca has unveiled plans to invest $2 billion in expanding its manufacturing footprint in Maryland, marking a significant step in the company’s broader strategy to strengthen its presence in the United States.
The investment is part of AstraZeneca’s long-term vision of deploying around $50 billion in US-based manufacturing and research activities by 2030. As part of this phase, the company will upgrade its biologics manufacturing facility in Frederick and establish a new cutting-edge clinical manufacturing campus in Gaithersburg.
The expansion in Frederick is expected to nearly double the facility’s commercial biologics production capacity. It will also bring new capabilities to support AstraZeneca’s rare-disease treatments — an area the company is increasingly prioritising. Meanwhile, the Gaithersburg campus will focus on clinical trial supply and advanced drug-substance manufacturing, with operations targeted to begin in 2029.
AstraZeneca anticipates that these projects will generate close to 2,600 new jobs across the two sites. This includes hundreds of specialised roles within manufacturing and research, along with a substantial number of construction jobs required for the build-outs.
The company’s latest push aligns with a growing trend among global pharmaceutical manufacturers to increase domestic production in the US. This shift is driven by heightened focus on supply-chain security, regulatory expectations, and the need to ensure resilient access to essential therapies.
AstraZeneca’s leadership noted that the Maryland investments reflect the firm’s commitment to expanding biologics capacity, accelerating development of rare-disease medicines, and meeting rising demand in one of its most critical markets. The company has been steadily increasing its US manufacturing capabilities, with recent expansions in cell therapy, drug-substance production, and biopharma operations across multiple states.
With this $2 billion commitment, AstraZeneca signals a renewed focus on building a robust, future-ready manufacturing ecosystem in the United States - supporting innovation, economic growth, and patient access to next-generation therapies.